Figure 2.

Efficacy of a) Lopinavir/r [21]and b) Darunavir/r monotherapy vs comparator arms [7,20]. Efficacy was assessed in the ITT population and modification of treatment was considered failure in the MONET and MONOI darunavir/r monotherapy trials [7,20]. In the lopinavir/r monotherapy trials [21], there was some variance in what was considered failure. In OK04 2005, treatment modification = failure. In OK04 2008, treatment modification ≠ failure. In KALMO failure was defined as confirmed HIV-1 RNA > 1,000 copies/mL. In MO6-613 non-responders were defined as those who either did not complete 96 weeks of treatment, had HIV-1 RNA at > 50 copies/mL at week 96, or experienced confirmed virological rebound before week 96.